000166090 001__ 166090
000166090 005__ 20260119170326.0
000166090 0247_ $$2doi$$a10.1007/s12094-025-03854-9
000166090 0248_ $$2sideral$$a147504
000166090 037__ $$aART-2025-147504
000166090 041__ $$aeng
000166090 100__ $$aGalindo Torres, Blanca Pilar
000166090 245__ $$aNew evidence for miRNA testing in head and neck squamous cell cancer patients
000166090 260__ $$c2025
000166090 5060_ $$aAccess copy available to the general public$$fUnrestricted
000166090 5203_ $$aPurpose: Prognosis of HNSCC has not changed over the last decades. MicroRNAs mediate gene expression and participate in regulating cellular biological processes. Its aberrant expression is an important event in the development of several cancers, including head and neck squamous cell cancer. The aim of the study is to determine if circulating miRNAs are reliable diagnostic indicators and can be used to monitor head
and neck cancer.
Methods/Patients: An observational, longitudinal, prospective, analytical study was conducted, with a case-control design, in which 37 head and neck squamous cell cancer patients at diagnosis were compared with 30 healthy patients. Blood samples were obtained and free miRNA expression levels of 17 miRNAs were determined by PCR-RT. Follow-up of HNSCC was carried out for one year with blood extractions at 7 days for surgical patients, and 1, 2, 6 and 12 months after finishing treatment for all patients.
Results: Seventy-eight percent of the participants in HNSCC group and 57% among control group were men. Smokers and alcohol consumers exhibit increased susceptibility to HNSCC, and risk rises to 63,4% (R2 = 0,634) when both factors are combined. HNSCC patients overexpressed miR-21-5p and miR-122, while miR-195-5p is downregulated. Elevated miR-21-5p levels correlates with tumour size and miR- 374b-5p, with advanced stage (p=0.005).
Conclusion: Our findings suggest that the evaluation of certain miRNAs’ expression levels in plasma can be used as potential markers for HNSCC diagnosis. Further assays with larger samples could be performed to validate data and establish a cut-off
000166090 540__ $$9info:eu-repo/semantics/embargoedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000166090 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000166090 700__ $$aAlcaraz Ortega, Raquel
000166090 700__ $$aSaiz López, Patricia
000166090 700__ $$0(orcid)0000-0002-3265-504X$$aAdiego Leza, María Isabel$$uUniversidad de Zaragoza
000166090 700__ $$aMoradillo Renuncio, María del Mar
000166090 700__ $$aGarcía Girón, Carlos
000166090 700__ $$aGrijalba Uche, Miguel Víctor
000166090 7102_ $$11013$$2653$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Otorrinolaringología
000166090 773__ $$g27, 8 (2025), 3399-3409$$pClin. transl. oncol.$$tClinical and Translational Oncology$$x1699-048X
000166090 8564_ $$s1577070$$uhttps://zaguan.unizar.es/record/166090/files/texto_completo.pdf$$yPostprint$$zinfo:eu-repo/date/embargoEnd/2026-02-06
000166090 8564_ $$s2305348$$uhttps://zaguan.unizar.es/record/166090/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint$$zinfo:eu-repo/date/embargoEnd/2026-02-06
000166090 909CO $$ooai:zaguan.unizar.es:166090$$particulos$$pdriver
000166090 951__ $$a2026-01-19-14:39:47
000166090 980__ $$aARTICLE